Interferon-γ-induced differentiation of human neuroblastoma cells increases cellular uptake and halflife of metaiodobenzylguanidine

P. G. Montaldo, R. Carbone, P. Cornaglia Ferraris, M. Ponzoni

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Iodine labeled metaiodobenzylguanidine (MIBG) is a radiopharmaceutical employed for both diagnosis and metabolic radiotherapy of neuroblastoma (NB). Resistance to the radiotherapeutic effects of MIBG is common, due to lack of MIBG accumulation by NB cells. MIBG enters competent cells via the noradrenaline transporter; this function requires a relative cellular maturation and is missing in most NB cell lines. In vitro differentiation of NB cells can be achieved with γ-interferon (γ-IFN) and other agents. We have verified that γ-IFN-induced differentiation of NB cells is specifically associated with an increase in their ability to incorporate MIBG. This phenomenon is due to enhancement of MIBG transporter activity, according to pharmacological sensitivity and semiquantitative PCR-based analysis of specific MIBG transporter mRNA. New therapeutic strategies, based on both differentiation therapy and targeted radiotherapy of NB can so be devised.

Original languageEnglish
JournalCytotechnology
Volume11
Issue number1 Supplement
DOIs
Publication statusPublished - Jan 1993

Fingerprint

Interferons
Radiotherapy
Neuroblastoma
Half-Life
Norepinephrine Plasma Membrane Transport Proteins
Radiopharmaceuticals
Iodine
Cells
Messenger RNA
Cell Differentiation
Pharmacology
Cell Line
Polymerase Chain Reaction
Therapeutics

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Cell Biology
  • Biotechnology

Cite this

Interferon-γ-induced differentiation of human neuroblastoma cells increases cellular uptake and halflife of metaiodobenzylguanidine. / Montaldo, P. G.; Carbone, R.; Cornaglia Ferraris, P.; Ponzoni, M.

In: Cytotechnology, Vol. 11, No. 1 Supplement, 01.1993.

Research output: Contribution to journalArticle

@article{052d277bb5464c6dbe450783dbfb2935,
title = "Interferon-γ-induced differentiation of human neuroblastoma cells increases cellular uptake and halflife of metaiodobenzylguanidine",
abstract = "Iodine labeled metaiodobenzylguanidine (MIBG) is a radiopharmaceutical employed for both diagnosis and metabolic radiotherapy of neuroblastoma (NB). Resistance to the radiotherapeutic effects of MIBG is common, due to lack of MIBG accumulation by NB cells. MIBG enters competent cells via the noradrenaline transporter; this function requires a relative cellular maturation and is missing in most NB cell lines. In vitro differentiation of NB cells can be achieved with γ-interferon (γ-IFN) and other agents. We have verified that γ-IFN-induced differentiation of NB cells is specifically associated with an increase in their ability to incorporate MIBG. This phenomenon is due to enhancement of MIBG transporter activity, according to pharmacological sensitivity and semiquantitative PCR-based analysis of specific MIBG transporter mRNA. New therapeutic strategies, based on both differentiation therapy and targeted radiotherapy of NB can so be devised.",
author = "Montaldo, {P. G.} and R. Carbone and {Cornaglia Ferraris}, P. and M. Ponzoni",
year = "1993",
month = "1",
doi = "10.1007/BF00746080",
language = "English",
volume = "11",
journal = "Cytotechnology",
issn = "0920-9069",
publisher = "Springer Netherlands",
number = "1 Supplement",

}

TY - JOUR

T1 - Interferon-γ-induced differentiation of human neuroblastoma cells increases cellular uptake and halflife of metaiodobenzylguanidine

AU - Montaldo, P. G.

AU - Carbone, R.

AU - Cornaglia Ferraris, P.

AU - Ponzoni, M.

PY - 1993/1

Y1 - 1993/1

N2 - Iodine labeled metaiodobenzylguanidine (MIBG) is a radiopharmaceutical employed for both diagnosis and metabolic radiotherapy of neuroblastoma (NB). Resistance to the radiotherapeutic effects of MIBG is common, due to lack of MIBG accumulation by NB cells. MIBG enters competent cells via the noradrenaline transporter; this function requires a relative cellular maturation and is missing in most NB cell lines. In vitro differentiation of NB cells can be achieved with γ-interferon (γ-IFN) and other agents. We have verified that γ-IFN-induced differentiation of NB cells is specifically associated with an increase in their ability to incorporate MIBG. This phenomenon is due to enhancement of MIBG transporter activity, according to pharmacological sensitivity and semiquantitative PCR-based analysis of specific MIBG transporter mRNA. New therapeutic strategies, based on both differentiation therapy and targeted radiotherapy of NB can so be devised.

AB - Iodine labeled metaiodobenzylguanidine (MIBG) is a radiopharmaceutical employed for both diagnosis and metabolic radiotherapy of neuroblastoma (NB). Resistance to the radiotherapeutic effects of MIBG is common, due to lack of MIBG accumulation by NB cells. MIBG enters competent cells via the noradrenaline transporter; this function requires a relative cellular maturation and is missing in most NB cell lines. In vitro differentiation of NB cells can be achieved with γ-interferon (γ-IFN) and other agents. We have verified that γ-IFN-induced differentiation of NB cells is specifically associated with an increase in their ability to incorporate MIBG. This phenomenon is due to enhancement of MIBG transporter activity, according to pharmacological sensitivity and semiquantitative PCR-based analysis of specific MIBG transporter mRNA. New therapeutic strategies, based on both differentiation therapy and targeted radiotherapy of NB can so be devised.

UR - http://www.scopus.com/inward/record.url?scp=0027345942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027345942&partnerID=8YFLogxK

U2 - 10.1007/BF00746080

DO - 10.1007/BF00746080

M3 - Article

C2 - 7763744

AN - SCOPUS:0027345942

VL - 11

JO - Cytotechnology

JF - Cytotechnology

SN - 0920-9069

IS - 1 Supplement

ER -